Cells of mouse spleen obtained 48 h after foster splenectomy, foster hepatectomy, resection of 2/3 of spleen or 36 h after resection of 2/3 of liver were introduced intravenously into partially hepatectomized (resection of 2/3 or 1/4 of liver) syngeneic recipients. Cells of regenerating spleen sharply inhibited the mitotic activity of cells of the recipient liver following resection of 1/4 of liver 48 h after the operation and introduction of cells. Inhibition proved to be dose-dependent: it became apparent when 30 million cells were introduced, increased at a dose of 60 million cells and remained at the same level at higher doses. Division of hepatocytes after resection of 1/4 of liver was inhibited by spleen cells taken in the donors 36 h after partial hepatectomy. Spleen cells of intact and pseudo-operated donors had no such ability. Introduction of 60 million of cells of the regenerating spleen and of the spleen of partially hepatectomized animals into recipients with resection of 2/3 of liver did not inhibit reliably the division of hepatocytes, thus indicating the dependence of inhibition on the level of suppressors in the organism. Resection of a major part of liver was accompanied by a greater decrease in the activity of endogenous suppressors which could not be recovered by the introduced cells. Inhibition of cell division by suppressors was not organ specific. Suppressors inhibited proliferation in liver irrespective of the site of operation.

Download full-text PDF

Source

Publication Analysis

Top Keywords

resection 2/3
16
spleen cells
12
partially hepatectomized
12
1/4 liver
12
cells
11
liver
9
liver syngeneic
8
2/3 liver
8
cells regenerating
8
regenerating spleen
8

Similar Publications

Background: Prospective randomized trials have demonstrated noninferior survival between sublobar resection and lobectomy in healthy non-small cell lung cancer (NSCLC) patients with tumors ≤2cm. However, some patient attributes are not well represented in randomized trials and uncertainty remains in the widespread applicability of randomized trial nodal dissection protocols.

Methods: Patients with ≤2cm, node-negative NSCLC (cT1N0) in the Society of Thoracic Surgeons prospective database were linked to Medicare survival data using a probabilistic matching algorithm.

View Article and Find Full Text PDF

Objective: To evaluate the feasibility of and long-term survival with combined organ resection for esophageal cancer (EC).

Background: The optimal treatment strategy for EC that is invading adjacent organs is not established.

Methods: Ninety patients with EC invading adjacent organs who underwent combined organ resection after induction treatments during 2003-2023 in our institute were eligible for the study.

View Article and Find Full Text PDF

. Lymph Node Ratio (LNR) is increasingly recognized as an important prognostic factor in various cancer types, with the potential to enhance patient stratification for intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma. The study aimed to assess the impact of LNR on survival in surgically resected patients with ICC and ECC.

View Article and Find Full Text PDF

Background: The purpose of this retrospective study was to evaluate the value of contrast-enhanced computed tomography (CE-CT) image features at baseline and after neoadjuvant chemotherapy in predicting histopathological response in patients with adenocarcinoma of the gastroesophageal junction (GEJ).

Methods: A total of 105 patients with a diagnosis of adenocarcinoma of the GEJ were examined by CE-CT at baseline and preoperatively after neoadjuvant chemotherapy. All patients underwent surgical resection.

View Article and Find Full Text PDF

Purpose: Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression is an emerging biomarker in gastric cancer and gastroesophageal junction cancer (GC). We assessed FGFR2b protein overexpression prevalence in nearly 3,800 tumor samples as part of the prescreening process for a global phase III study in patients with newly diagnosed advanced or metastatic GC.

Methods: As of June 28, 2024, 3,782 tumor samples from prescreened patients from 37 countries for the phase III FORTITUDE-101 trial (ClinicalTrials.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!